Home » Stocks » CGEN

Compugen Ltd. (CGEN)

Stock Price: $7.88 USD 0.06 (0.77%)
Updated Jun 21, 2021 12:46 PM EDT - Market open
Market Cap 695.18M
Revenue (ttm) 2.00M
Net Income (ttm) -32.48M
Shares Out 83.68M
EPS (ttm) -0.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 21
Last Price $7.88
Previous Close $7.82
Change ($) 0.06
Change (%) 0.77%
Day's Open 7.85
Day's Range 7.60 - 7.89
Day's Volume 300,065
52-Week Range 6.73 - 19.90

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Compugen Ltd (NASDAQ: CGEN) has announced updated data from its Phase 1 dose-escalation and expansion study of COM701 as a monotherapy and in a dose-escalation combination study with Bristol-Myers Squib...

1 week ago - Benzinga

HOLON, Israel, June 8, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, presented updated data from its Phase ...

1 week ago - PRNewsWire

HOLON, Israel, June 1, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that members of its s...

2 weeks ago - PRNewsWire

Investors liked what the company had to say in its Q1 update.

1 month ago - The Motley Fool

HOLON, Israel, May 13, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for ...

1 month ago - PRNewsWire

HOLON, Israel, May 11, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that Eran Ophir, Ph.D.

1 month ago - PRNewsWire

HOLON, Israel, May 10, 2021 /PRNewswire/ --  Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that it has expanded...

1 month ago - PRNewsWire

HOLON, Israel, May 3, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will ...

1 month ago - PRNewsWire

HOLON, Israel, April 29, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that it will presen...

1 month ago - PRNewsWire

HOLON, Israel, April 27, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the publication of ...

1 month ago - PRNewsWire

These seven stocks may be risky, but they also have the potential for big returns -- as all of them are stocks that could double by summer. The post 7 Stocks That Could Double by Summer appeared first o...

Other stocks mentioned: ATRA, BLI, CIDM, CRDF, KERN, ZDGE
2 months ago - InvestorPlace

HOLON, Israel, March 9, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the publication of a...

3 months ago - PRNewsWire

Other stocks mentioned: ARKF, ARKG, ARKK, ARKQ, ARKW, SSYS
3 months ago - GuruFocus

ARK Investment Management – or ARK Invest, as it usually styles itself – had a great 2020. ARK Innovation ETF (ARKK), the firm's flagship fund, returned more than 150% last year.

Other stocks mentioned: AMZN, ARKK, EDIT
3 months ago - GuruFocus

Compugen Ltd (NASDAQ: CGEN) reports updated data from its Phase 1 dose-escalation and expansion study of COM701 as a monotherapy and a dose-escalation combination study with Bristol-Myers Squibb Co's (N...

3 months ago - Benzinga

HOLON, Israel, Feb. 25, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for...

3 months ago - PRNewsWire

Compugen Ltd (NASDAQ: CGEN) expands its clinical collaboration agreement with Bristol-Myers Squibb Co (NYSE: BMY), wherein Bristol Myers will supply Opdivo (nivolumab) for Compugen's Phase 1b cohort exp...

3 months ago - Benzinga

HOLON, Israel, Dec. 23, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today progress from its on...

Other stocks mentioned: AZN
5 months ago - PRNewsWire

HOLON, Israel, Nov. 10, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that management will p...

7 months ago - PRNewsWire

Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q3 2020 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

HOLON, Israel, Sept. 30, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the addition of Nil...

8 months ago - PRNewsWire

HOLON, Israel, Sept. 8, 2020 /PRNewswire/ -- Compugen Ltd.

9 months ago - PRNewsWire

HOLON, Israel, Sept. 3, 2020 /PRNewswire/ -- Compugen Ltd.

9 months ago - PRNewsWire

HOLON, Israel, Aug. 28, 2020 /PRNewswire/ -- Compugen Ltd.

9 months ago - PRNewsWire

Compugen Ltd (CGEN) CEO Anat Dayag on Q2 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

HOLON, Israel, July 30, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for...

10 months ago - PRNewsWire

Compugen: Clinical Data Supports COM701 As A Potential Breakthrough Cancer Treatment

10 months ago - Seeking Alpha

HOLON, Israel, July 16, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company wil...

11 months ago - PRNewsWire

Compugen's Cancer Trial, And Other News: The Good, Bad And Ugly Of Biopharma

1 year ago - Seeking Alpha

HOLON, Israel, June 1, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the U.S. Food an...

1 year ago - PRNewsWire

Here are the hottest companies coming up in the biotech sector next month.

Other stocks mentioned: RHHBY, VRTX
1 year ago - The Motley Fool

Investors need to pay close attention to Compugen (CGEN) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

Compugen (CGEN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

1 year ago - Zacks Investment Research

Roche's Upcoming Phase 2 TIGIT Results At ASCO Could Read Through To Compugen's COM902 TIGIT Candidate

1 year ago - Seeking Alpha

Top Ranked Momentum Stocks to Buy for May 8th

Other stocks mentioned: CHGG, GNMK
1 year ago - Zacks Investment Research

Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Its new discovery in the field of cancer immunotherapy produced mixed clinical results, but it certainly has ample backing from the big players.

1 year ago - The Motley Fool

Does Compugen (CGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.

1 year ago - Zacks Investment Research

Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

1 year ago - Zacks Investment Research

When the financial markets enter their once-a-decade crisis mode, it often feels impossible to think rationally and to make normal investing decisions.

1 year ago - 24/7 Wall Street

Two patients treated with one of the biotech's drugs had partial responses.

1 year ago - The Motley Fool

Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Compugen Ltd.: Upcoming Catalysts In 2020 And 2021

1 year ago - Seeking Alpha

With stocks at all time highs and after the Dow rose more than 22% and the S&P 500 rose over 28% in 2019, many investors have yet to make many changes in the portfolios for what could be another solid 2...

Other stocks mentioned: GLUU, GME, GRPN, IDXG, MEET, OGI, RTIX ...
1 year ago - 24/7 Wall Street

Compugen shares rebounded Thursday after Cantor Fitzgerald initiated coverage with an Overweight rating and a $10 price target.

1 year ago - Investopedia

The biotech sector has had a good run in 2019 on the back of ongoing M&A activities and positive pipeline updates.

Other stocks mentioned: ACAD, CUE, EPZM, QURE
1 year ago - Zacks Investment Research

Does Compugen (CGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.

1 year ago - Zacks Investment Research

Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 year ago - Zacks Investment Research

Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

About CGEN

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; BAY 1905254, a therapeutic antibody targeting ILDR2, which is in Phase I clinical study in patients with solid tumors; and COM902, a therapeutic antibody targeting TIGIT. Its ... [Read more...]

Industry
Biotechnology
IPO Date
Aug 11, 2000
Stock Exchange
NASDAQ
Ticker Symbol
CGEN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for Compugen stock is "Strong Buy." The 12-month stock price forecast is 21.29, which is an increase of 170.18% from the latest price.

Price Target
$21.29
(170.18% upside)
Analyst Consensus: Strong Buy